--- title: "MoonLake Immunotherapeutics | 8-K: FY2026 Q2 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/295397771.md" datetime: "2026-08-10T11:17:13.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295397771.md) - [en](https://longbridge.com/en/news/295397771.md) - [zh-HK](https://longbridge.com/zh-HK/news/295397771.md) generator: "portal-rs" --- # MoonLake Immunotherapeutics | 8-K: FY2026 Q2 Revenue: USD 0 Revenue: As of FY2026 Q2, the actual value is USD 0. EPS: As of FY2026 Q2, the actual value is USD -0.84, beating the estimate of USD -0.926. EBIT: As of FY2026 Q2, the actual value is USD -59.08 M. ### Financial Position MoonLake Immunotherapeutics reported cash, cash equivalents, and short-term marketable debt securities totaling $537.0 million as of June 30, 2026, an increase from $357,921 thousand as of March 31, 2026, which included cash and cash equivalents of $298,490 thousand and short-term marketable debt securities of $59,431 thousand. ### Operating Expenses Research and development expenses for the three months ended June 30, 2026, were - $50,221 thousand, a decrease from - $54,515 thousand for the three months ended March 31, 2026. General and administrative expenses were - $11,439 thousand for the three months ended June 30, 2026, down from - $15,509 thousand for the three months ended March 31, 2026. This decrease of $4.1 million was primarily due to a $4.8 million accelerated expense recognition in the prior quarter related to a voluntary cancellation of unvested stock option awards. Total operating expenses for the three months ended June 30, 2026, were - $61,660 thousand, compared to - $70,024 thousand for the three months ended March 31, 2026. ### Operating Loss and Net Loss The company reported an operating loss of - $61,660 thousand for the three months ended June 30, 2026, versus - $70,024 thousand for the three months ended March 31, 2026. The net loss was - $61,805 thousand for the three months ended June 30, 2026, compared to - $69,707 thousand for the three months ended March 31, 2026. Basic and diluted net loss per share was - $0.84 for the three months ended June 30, 2026, an improvement from - $0.98 for the three months ended March 31, 2026. ### Other Financial Items Interest expense was - $2,632 thousand for the three months ended June 30, 2026, and - $2,269 thousand for the three months ended March 31, 2026. Other income, net, was $2,577 thousand and $3,208 thousand for the respective periods. Income tax expense was - $90 thousand for the three months ended June 30, 2026, and - $622 thousand for the three months ended March 31, 2026. Comprehensive loss was - $61,497 thousand for the three months ended June 30, 2026, compared to - $69,989 thousand for the three months ended March 31, 2026. ### Balance Sheet Highlights Total assets increased to $573,947 thousand as of June 30, 2026, from $400,374 thousand as of March 31, 2026. Total liabilities were $145,752 thousand as of June 30, 2026, a slight decrease from $146,350 thousand as of March 31, 2026. Total shareholders’ equity rose to $428,195 thousand as of June 30, 2026, from $254,024 thousand as of March 31, 2026. The accumulated deficit was - $594,423 thousand as of June 30, 2026, compared to - $532,618 thousand as of March 31, 2026. ### Operational Metrics (IZAR-1 Phase 3 Trial Results) MoonLake Immunotherapeutics announced positive topline results from the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis, with the 60 mg sonelokimab with induction arm meeting all clinical endpoints at Week 16. The primary endpoint of ACR50 was met with a 42.1% response rate. Key secondary endpoints showed significant responses: ACR20 at 66.5%, MDA at 41.2%, and PASI90 at 61% in patients with concomitant skin involvement. Clinically meaningful improvements were also observed in patient-reported outcomes, with a mean change from baseline in HAQ-DI of -0.427 and an improvement in SF-36 Physical Component Summary (PCS) score of 6.54. The blinded safety analysis indicated a profile consistent with previous studies, with no new safety signals identified. ### Outlook / Guidance MoonLake Immunotherapeutics anticipates a cash runway extending to mid-2028, supported by up to $400 million in non-dilutive funds from its debt facility. Key upcoming milestones include the expected submission of a Biologics License Application (BLA) for HS by the end of September 2026, and the expected allocation of a PDUFA date and decision on Priority Review by the end of November 2026. The company also expects to commence enrollment in the Palmoplantar Pustulosis (PPP) Phase 3 trial in H2 2026, complete enrollment in the PsA – IZAR-2 trial in Q3 2026, and report results from the P-OLARIS trial by the end of 2026 or early 2027. ### Related Stocks - [MLTX.US](https://longbridge.com/en/quote/MLTX.US.md) ## Related News & Research - [Dimensional Fund Advisors LP Has $490,000 Position in MoonLake Immunotherapeutics $MLTX](https://longbridge.com/en/news/296016200.md) - [MoonLake's psoriatic arthritis drug meets key goals in late-stage trial](https://longbridge.com/en/news/295404482.md) - [MoonLake Immunotherapeutics CSO Kristian Reich disposes of $1 million in common shares](https://longbridge.com/en/news/293660700.md) - [Switzerland's MoonLake Q2 net loss narrows as expenses fall](https://longbridge.com/en/news/295397074.md) - [MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study](https://longbridge.com/en/news/295434879.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**